

SUPPLEMENTAL FIGURE 1. Combining unconjugated antibodies with PT-RAIT.

BALB/c nude mice bearing s.c. Ramos tumors were given a PT-RAIT with or without an unconjugated antibody. For PT-RAIT, TF4 was given 29.5 h before the injection of ^{90}Y -IMP-288 (T_0). Arrows indicate the time when the unconjugated antibodies were given. Each growth curve shows the fraction of animals cured (S) and median time to 2.5 cm^3 (MS). (A) Untreated; (B) Two mg epratuzumab (hLL2) on T_0 , followed weekly x 3 with 0.5 mg epratuzumab (arrows). (C) One mg milatuzumab (hLL1) given at T_0 followed weekly x 2 with 0.5 mg milatuzumab (arrows); (D) One mg veltuzumab (hA20) given T_0 , with 3 x 0.5 mg veltuzumab given weekly (arrows); (E) 2.25 nmoles ($355\text{ }\mu\text{g}$) followed 29 h later with 9.24 MBq (0.25 mCi ; 0.09 nmoles) ^{90}Y -IMP-288 (T_0). (F) 2.4 nmoles ($384\text{ }\mu\text{g}$) TF4 followed 29 h later 7.4 MBq (0.2 mCi ; 0.12 nmoles) ^{90}Y -IMP-288 (T_0). Two mg epratuzumab (hLL2) was given 2 days later, and then weekly x 3 with 0.5 mg (arrows). (G) Treatment ‘E’ combined with 1 mg milatuzumab given at T_0 , followed weekly x 3 with 0.5 mg hLL1 (arrows). (H) Treatment ‘E’ combined with 1 mg veltuzumab starting 1 week after the ^{90}Y -IMP-288 with weekly x 3 doses of 0.5 mg veltuzumab (arrows).

